Before many people get the third shot, a new warning from the Moderna CEO comes here.Recently, he said publicly that as the drug effectiveness will decline over time, people may need a fourth dose in the fall to boost protection.
Stephane Bancel said people receiving booster needles last fall may have enough protection against the virus this winter.But the efficacy of the booster needle may decline over a few months, similar to the case of the first two needles.
The highly contagious omicron is currently spreading globally, with an unprecedented surge in infections.The seven-day average exceeded 574,000 per day, according to Johns Hopkins University.
“I believe that in the fall of 22 we need to be booster again.In addition, older or individuals with potential health problems may need to receive a booster needle annually in the coming years.We keep saying that the virus should not disappear and that we will have to put up with it “.
Preliminary data released by Moderna last month showed that the 50 currently approved micrograms of booster needles raised antibodies blocking omicron infection by 37 times and 100 micrograms by 83 times.Data from the UK found that Moderna and Pfizer were only about 10% effective in preventing symptomatic infections, 20 weeks after the second dose.
The booster needle was 75% effective in preventing symptomatic infections two weeks after needle injection.But the effect began to decline after about four weeks, reducing the effectiveness to 55% to 70% at 5 to 9 weeks, and 40% to 50% after 10 weeks.In addition to Moderna, Pfizer’s CEO also publicly said last week that people may need a fourth vaccine because of omicron infectivity, and possibly earlier than expected.
According to a new study released by the Institute of Clinical Evaluation Sciences (ICES), the two doses of the vaccine will not stop infecting the Orikjon variant, and even with the third dose, the vaccine is only 37 percent protective.However, vaccination has a great effect in reducing severe illness and death.
In response to the data reported between 22 November and 19 December 2021, the ICES investigated the effectiveness of the ” vaccine against infecting Omilkjon or Delta.
In controls, 3,442 Omicjon positive, 9,201 Delta positive and 471,545 negative cases were found infected.——-
Obviously young (average age of infection is 34.9 years, negative average 45 years);
More likely to be a male;
Any complications are unlikely to occur;
“Having had multiple tests before” is less likely;
“Less likely to have tested positive”;
“Less likely to get a flu vaccine in the first two flu seasons.”;
Infection was more likely to occur later in the study period (i. e., mid-December);
“With two doses” is more likely;
“A third dose” is less likely.
The study also found:
The average age of omicron patients was 34, significantly lower than the average age of Delta patients, 43.
The effectiveness of the vaccine against Delta declined steadily over time after two doses. But seven days after the third dose of mRNA vaccine, the effectiveness of the vaccine recovered to 93%.
Two vaccinations are unlikely to prevent omicron infection. A third dose provides some protection in the short term, but is much less effective than protection against infection with Delta.
Of the 3,442 omicron cases, 176 (5.1%) were not vaccinated; 3102 cases received two doses of vaccine (90.1%); A third dose of vaccine was administered in 164 cases (4.8%).
Of the 164 people who got the third dose, 90 percent got Pfizer and 10 percent modena.
The “rich” were more likely to get Omicron than the “poor” — 11 percent in the bottom 20 percent of incomes, compared with 33.5 percent in the top 20 percent.
Runny nose and sore throat are not the only common symptoms of Omicron.
The ZOEnovel Coronavirus Symptoms Study, the UK-led outbreak tracking app, has catalogued 20 common symptoms of infection with the Omicron variant. The top five are runny nose, headache, fatigue, sneezing and sore throat. Other symptoms include a persistent cough, hoarse voice, chills, fever, dizziness, brain fog, abnormal sense of smell, sour eyes, unusual muscle aches, loss of appetite, loss of smell, chest pain, swollen glands and low mood.
A series of studies found that the Omicron variant was actually less virulent than other variants, and the first official report in the UK showed that the Omicron variant had a 50% to 70% lower risk of hospitalization than Delta. British health officials have repeatedly said that booster shots can prevent infection with the Omicron variant.
ZOE group leader Claire, clinical senior lecturer at King’s College London. Claire Steves, the UK’s director of health, also urged people in the UK to make sure they get booster shots. She noted that data from ZOE’s team showed that nearly 50 percent of new confirmed cases were among people who had received only two doses of vaccine.
Steve urged caution in the UK over the coming weeks, warning that the health system was already under huge strain and that the rest of January would be an experiment. She said it would go a long way to stopping the spread of the disease if everyone eligible got booster shots, wore masks, got tested and recorded new symptoms.
Post time: Jan-10-2022